<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924754</url>
  </required_header>
  <id_info>
    <org_study_id>13366</org_study_id>
    <nct_id>NCT01924754</nct_id>
  </id_info>
  <brief_title>Gardasil Immunogenicity With Needle-Free Injection</brief_title>
  <acronym>GINI</acronym>
  <official_title>GINI: Gardasil Immunogenicity With Needle-free Injection-Safety and Immunogenicity of Gardasil Using IM and ID Needle-free Injection Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that&#xD;
      studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at&#xD;
      UCSF will be testing the serum for antibodies to measure the strength of their response to&#xD;
      the vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives&#xD;
&#xD;
        1. Compared rates of seroconversion and geometric mean titers (GMTs) generated following a&#xD;
           3-dose series of vaccine in women given low doses of vaccine by the intradermal (ID)&#xD;
           route with the needle-free injector (NFI) (Group III) to those women given standard&#xD;
           doses by the intramuscular (IM) route with a needle and syringe (Group I) at 1 month, 6&#xD;
           months and 12 months following completion of the vaccination series.&#xD;
&#xD;
        2. Compared rates of seroconversion and GMTs generated following a 3-dose series of vaccine&#xD;
           in women given standard doses of vaccine by the IM route with the NFI (Group II) to&#xD;
           those women given standard doses by the IM route with a needle and syringe (Group I) at&#xD;
           1 month, 6 months and 12 months following completion of the vaccination series.&#xD;
&#xD;
      Serum samples were collected on 4 successive occasions: (1) day zero, prior to the first&#xD;
      immunization, (2) at visit 4, one month following the third and final immunization, (3) at&#xD;
      visit 5 (12 months) and (4) and at visit 6 (24 months after enrollment). Samples were split,&#xD;
      stored and transferred in batch for analysis.&#xD;
&#xD;
      Merck received samples for processing and determined the geometric mean titer of antibodies&#xD;
      specific to HPV (types 6, 11, 16, and 18) and results were transferred to the principal&#xD;
      investigator. The University of California, San Francisco (UCSF) used a portion of the&#xD;
      collected blood samples for pseudovirion-based neutralisation assay (PBNA) analysis conducted&#xD;
      at UCSF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">May 31, 2016</completion_date>
  <primary_completion_date type="Actual">May 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Geometric Mean Antibody Concentrations by HPV Type</measure>
    <time_frame>Baseline, up to 1 day</time_frame>
    <description>Geometric mean antibody concentrations above the lower limit of assay detection at baseline were assessed by HPV type</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Demonstrated Seroconversion for HPV 6</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 6 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Demonstrated Seroconversion for HPV 11</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 11 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Demonstrated Seroconversion for HPV 16</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 16 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Demonstrated Seroconversion for HPV 18</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 18 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Concentration for HPV 6 Over Time</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The median (mMU/mL) for HPV 6 at month 7 for the intent to treat population was calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Concentration for HPV 11 Over Time</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The median concentration (mMU/mL) for HPV 11 at month 7 for the intent to treat population was calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Concentration for HPV 16 Over Time</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The median concentration (mMU/mL) for HPV 16 at month 7 for the intent to treat population was calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Concentration for HPV 18 Over Time</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The median concentration (mMU/mL) for HPV 18 at month 7 for the intent to treat population was calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration Ratio of NS-IM Versus the PharmaJet Groups by HPV Type</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>The Geometric Mean Concentration Ratio (GMCR) and 95% confidence interval for both NS-IM versus JI-IM and NS-IM versus JI-ID was computed for the intent to treat population. Non-inferiority for arms JI-IM and JI-ID was defined as geometric mean concentration ratio (GMCR) &lt;1.5 of NS-IM at month 7</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>HPV Seroconversion</condition>
  <arm_group>
    <arm_group_label>Standard intramuscular injection (NS-IM)</arm_group_label>
    <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe (NS-IM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PharmaJet needle-free Stratis device (JI-IM)</arm_group_label>
    <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device (JI-IM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PharmaJet needle-free Tropis device (JI-ID)</arm_group_label>
    <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device (JI-ID)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study was for women and focused on the safety and immunogenicity of the HPV vaccine.&#xD;
        Separate studies will be done in men if the dosing regimens in Groups II or III are shown&#xD;
        to be non-inferior to the standard regimen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Thai women age 18-26 years&#xD;
&#xD;
          -  No more than 5 lifetime sexual partners&#xD;
&#xD;
          -  HIV-uninfected&#xD;
&#xD;
          -  No history of HPV vaccination&#xD;
&#xD;
          -  Judged able to complete all of the protocol visits&#xD;
&#xD;
          -  No contraindications to vaccination with Gardasil&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Does not satisfy all of the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Palefsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>September 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2021</results_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Gardasil</keyword>
  <keyword>seroconversion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>161 women visiting the Thai Red Cross Anonymous Clinic between February 2014 and April 2014 were invited to participate in the study and were screened after providing informed consent. Eleven women were determined to be ineligible</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Intramuscular Injection (NS-IM)</title>
          <description>Human papillomavirus (HPV) vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
        </group>
        <group group_id="P2">
          <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
          <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
        </group>
        <group group_id="P3">
          <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
          <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Intramuscular Injection (NS-IM)</title>
          <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
        </group>
        <group group_id="B2">
          <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
          <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
        </group>
        <group group_id="B3">
          <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
          <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" lower_limit="22.0" upper_limit="24.4"/>
                    <measurement group_id="B2" value="23.4" lower_limit="21.2" upper_limit="24.9"/>
                    <measurement group_id="B3" value="24.5" lower_limit="22.9" upper_limit="25.3"/>
                    <measurement group_id="B4" value="23.7" lower_limit="22.1" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive cervical HPV DNA at Baseline</title>
          <description>A larger proportion of cases of cervical cancer are caused by infection with HPV types 16 or 18 . HPV types 6 and 11 are low-risk types and cause a majority of anogenital warts in women and men</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>HPV-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of HPV genotypes detected at Baseline</title>
          <description>Persons can be infected with more than one HPV genotype</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1 type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 3 types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Geometric Mean Antibody Concentrations by HPV Type</title>
        <description>Geometric mean antibody concentrations above the lower limit of assay detection at baseline were assessed by HPV type</description>
        <time_frame>Baseline, up to 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>Human papillomavirus (HPV) vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Geometric Mean Antibody Concentrations by HPV Type</title>
          <description>Geometric mean antibody concentrations above the lower limit of assay detection at baseline were assessed by HPV type</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 6</title>
        <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 6 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 6</title>
          <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 6 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97.2"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 11</title>
        <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 11 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 11</title>
          <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 11 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 16</title>
        <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 16 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 16</title>
          <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 16 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97.4"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 18</title>
        <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 18 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Demonstrated Seroconversion for HPV 18</title>
          <description>The percentage of participants with demonstrated seroconversion generated following a 3-dose series of vaccine for antibodies to HPV 18 at month 7 for the per-protocol efficacy population. The per-protocol efficacy population is defined as as those with month 7 result available, geometric mean antibody concentration below the cutoff level for positivity and undetectable baseline cervical HPV DNA.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97.6"/>
                    <measurement group_id="O3" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Concentration for HPV 6 Over Time</title>
        <description>The median (mMU/mL) for HPV 6 at month 7 for the intent to treat population was calculated</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Median Concentration for HPV 6 Over Time</title>
          <description>The median (mMU/mL) for HPV 6 at month 7 for the intent to treat population was calculated</description>
          <units>mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="11" lower_limit="11" upper_limit="11"/>
                    <measurement group_id="O3" value="11" lower_limit="11" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449.5" lower_limit="271" upper_limit="750"/>
                    <measurement group_id="O2" value="311" lower_limit="247" upper_limit="665"/>
                    <measurement group_id="O3" value="259.5" lower_limit="146" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Concentration for HPV 11 Over Time</title>
        <description>The median concentration (mMU/mL) for HPV 11 at month 7 for the intent to treat population was calculated</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Median Concentration for HPV 11 Over Time</title>
          <description>The median concentration (mMU/mL) for HPV 11 at month 7 for the intent to treat population was calculated</description>
          <units>mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="8" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="8" upper_limit="8"/>
                    <measurement group_id="O3" value="8" lower_limit="8" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517.5" lower_limit="334" upper_limit="769"/>
                    <measurement group_id="O2" value="484" lower_limit="249" upper_limit="772"/>
                    <measurement group_id="O3" value="387" lower_limit="197" upper_limit="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Concentration for HPV 16 Over Time</title>
        <description>The median concentration (mMU/mL) for HPV 16 at month 7 for the intent to treat population was calculated</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Median Concentration for HPV 16 Over Time</title>
          <description>The median concentration (mMU/mL) for HPV 16 at month 7 for the intent to treat population was calculated</description>
          <units>mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="11" upper_limit="26"/>
                    <measurement group_id="O2" value="11" lower_limit="11" upper_limit="11"/>
                    <measurement group_id="O3" value="11" lower_limit="11" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2243.5" lower_limit="1669" upper_limit="4227"/>
                    <measurement group_id="O2" value="2054.5" lower_limit="1297" upper_limit="3332"/>
                    <measurement group_id="O3" value="1482" lower_limit="730" upper_limit="2584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Concentration for HPV 18 Over Time</title>
        <description>The median concentration (mMU/mL) for HPV 18 at month 7 for the intent to treat population was calculated</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intramuscular Injection (NS-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O3">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Median Concentration for HPV 18 Over Time</title>
          <description>The median concentration (mMU/mL) for HPV 18 at month 7 for the intent to treat population was calculated</description>
          <units>mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="10"/>
                    <measurement group_id="O3" value="10" lower_limit="10" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.5" lower_limit="193" upper_limit="768"/>
                    <measurement group_id="O2" value="414.5" lower_limit="166" upper_limit="610"/>
                    <measurement group_id="O3" value="372.5" lower_limit="142" upper_limit="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration Ratio of NS-IM Versus the PharmaJet Groups by HPV Type</title>
        <description>The Geometric Mean Concentration Ratio (GMCR) and 95% confidence interval for both NS-IM versus JI-IM and NS-IM versus JI-ID was computed for the intent to treat population. Non-inferiority for arms JI-IM and JI-ID was defined as geometric mean concentration ratio (GMCR) &lt;1.5 of NS-IM at month 7</description>
        <time_frame>Up to 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
            <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
          </group>
          <group group_id="O2">
            <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
            <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration Ratio of NS-IM Versus the PharmaJet Groups by HPV Type</title>
          <description>The Geometric Mean Concentration Ratio (GMCR) and 95% confidence interval for both NS-IM versus JI-IM and NS-IM versus JI-ID was computed for the intent to treat population. Non-inferiority for arms JI-IM and JI-ID was defined as geometric mean concentration ratio (GMCR) &lt;1.5 of NS-IM at month 7</description>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="0.90" upper_limit="2.08"/>
                    <measurement group_id="O2" value="1.84" lower_limit="1.30" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="0.94" upper_limit="1.96"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.19" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="0.97" upper_limit="2.24"/>
                    <measurement group_id="O2" value="1.97" lower_limit="1.34" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.79" upper_limit="1.91"/>
                    <measurement group_id="O2" value="1.52" lower_limit="0.99" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 months</time_frame>
      <desc>Immediate complaints (noted within 30 minutes after vaccination), solicited adverse events (local and systemic) from the first day after vaccination until 7 days after the vaccination as reported on diary cards, and unsolicited reported adverse events during the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Intramuscular Injection (NS-IM)</title>
          <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe</description>
        </group>
        <group group_id="E2">
          <title>PharmaJet Needle-free Stratis Device (JI-IM)</title>
          <description>HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device</description>
        </group>
        <group group_id="E3">
          <title>PharmaJet Needle-free Tropis Device (JI-ID)</title>
          <description>HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arm movement limitation</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joel Palefsky, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 476-8885</phone>
      <email>Joel.Palefsy@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

